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Abstract 
 
Astrocytes, the most abundant glial cells of the central nervous system are morphologically complex. They 
display numerous processes interacting with synapses and blood vessels. At the vascular interface, 
astrocyte endfeet-terminated processes almost entirely cover the blood vessel surface and participate to 
the gliovascular unit where important vascular properties of the brain are set such as the blood-brain 
barrier (BBB) integrity. How specific morphological and functional interactions between astrocytes and 
the vascular compartment develop has not been fully investigated. Here, we elaborated an original 
experimental strategy to study the postnatal development of astrocyte perivascular endfeet. Using purified 
gliovascular units, we focused on the postnatal expression of MLC1 and GlialCAM, two transmembrane 
proteins forming a complex enriched at the junction between mature astrocyte perivascular endfeet. We 
showed that MLC1 and GlialCAM were enriched and assembled into mature complexes in astrocyte 
perivascular endfeet between postnatal days 10 and 15, after the formation of astrocyte perivascular 
Aquaporin 4 water channels. These events correlated with the increased expression of Claudin-5 and P-
gP, two endothelial-specific BBB components. These results illustrate for the first time that astrocyte 
perivascular endfeet differentiation is a complex and progressive process which correlates with BBB 
maturation. Moreover, our results suggest that maturation of the astrocyte endfeet MLC1/GlialCAM 
complex between postnatal days 10 and 15 might be a key event in the gliovascular unit maturation. 
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Introduction 
Astrocytes are glial cells now recognized as key actors of the brain physiology (Vasile et al. 2017; Allen and 
Eroglu 2017). They closely interact with both the neuronal and the vascular compartments, maintaining and 
modulating synaptic and brain vascular functions. At the vascular interface, astrocytes are involved in the 
coupling between blood flow and neuronal activity (Attwell et al. 2010). They maintain blood-brain barrier 
(BBB) integrity by contributing to the basal lamina composition (Menezes et al. 2014) or controlling the 
expression of endothelial tight junction proteins and transporters (Abbott et al. 2006). They regulate perivascular 
homeostasis and fluid circulation (Amiry-Moghaddam et al. 2004; Iliff et al. 2012). They play a key role in brain 
immune quiescence, controlling the recruitment and fate of immune cells and influencing inflammatory 
processes in the brain (Alvarez et al. 2013). Astrocyte regulation of brain vascular functions is sustained by a 
morphological and molecular polarity. At the vascular interface, they send processes called endfeet which almost 
entirely cover the brain vasculature and form together with endothelial and mural cells (pericytes or smooth 
muscle cells) the gliovascular unit (GVU) (Mathiisen et al. 2010). They are equipped with a molecular repertoire 
dedicated to the regulation of the vascular system, which includes the gap junction proteins Connexin 30 and 43  
(Boulay et al. 2015b, a) and the water channel Aquaporin 4 (Aqp4) (Amiry-Moghaddam et al. 2004; Hawkes et 
al. 2011). How this specialized astrocyte interface with the vascular system is set during development is 
unknown. Vessels are formed during embryonic development from a perineural vascular plexus. They penetrate 
the neuroectoderm and form immature blood vessels. Around embryonic day (E) 15 in the mouse, neighboring 
cells such as pericytes induce a primitive endothelial BBB (Ben-Zvi et al. 2014; Chen et al. 2017). At birth, 
while angiogenesis is mainly completed, acquisition of brain-specific vascular functions continues, in particular 
BBB maturation (Obermeier et al. 2013) and neurovascular coupling (Schmithorst et al. 2015). Astrocytes are 
generated from radial glia around E17 and astrocytogenesis continues in the neonates, mainly by local division 
(Ge et al. 2012; Nagao et al. 2016; Jiang and Nardelli 2016). Astrocyte maturation is achieved by integration 
within their environment in particular through the formation of polarized processes interacting with blood 
vessels (Stogsdill et al. 2017). Based on the expression of Aqp4, previous studies suggested that astrocyte 
endfeet perivascular coverage starts around E18 in the mouse and is complete at P5 in the cortex (Ezan et al. 
2012) and around P13 in pial vessels (Lunde et al. 2015). However, a precise description of how and when 
astrocyte endfeet acquire their molecular repertoire and their specific functions is still lacking.  
To address this question, we focused here on MLC1 and GlialCAM, two membrane proteins forming a 
junctional complex enriched between astrocyte perivascular endfeet in the adult brain (Teijido et al. 2007; 
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Hoegg-Beiler et al. 2014). Mutations in their associated genes are linked to Megalencephalic 
Leukoencephalopathy with subcortical Cysts (MLC), a rare type of leukodystrophy characterized by progressive 
macrocephaly, that leads to the degradation of motor functions and mental retardation (van der Knaap et al. 
2012). In the brain, MLC1 is exclusively expressed by astrocytes and enriched in perivascular endfeet. It has 
been shown to play a role in osmotic regulations either directly or indirectly through its interaction with other 
proteins such as the chloride channel CLC-2 (Sirisi et al. 2014). Despite MLC1 similarity with ion channels and 
transporters, its function is yet unknown. GlialCAM is a member of the immunoglobulin superfamily of cellular 
adhesion proteins and is expressed in the brain by astrocytes and oligodendrocytes (Chung Moh et al. 2005; 
Favre-Kontula et al. 2008). It interacts directly with MLC1 and is crucial for its compartmentalization at the 
astrocyte membrane (López-Hernández et al. 2011b; Jeworutzki et al. 2012). It also protects MLC1 from 
degradation by acting as a chaperone (Capdevila-Nortes et al. 2013a). Previous reports showed that MLC1 
expression starts around E16 in the mouse brain, mainly in progenitor cells from the ventricular zone, and 
increases specifically in astrocytes until 3 weeks postnatal (Schmitt et al. 2003), while GlialCAM expression 
increases from birth (Bugiani et al. 2017).  
Here, taking advantage of our recently described GVU purification technique (Boulay et al. 2015c, 2017), we 
characterized the astrocyte perivascular endfeet MLC1 and GlialCAM expression during postnatal development. 
We show that GlialCAM precedes MLC1 expression and that both proteins increase in already formed Aqp4-
expressing astrocyte perivascular endfeet between P10 and P15, in parallel to the BBB maturation. Our results 
provide the first evidence that astrocyte endfeet development is a stepwise process with sequential acquisition of 
a polarized molecular repertoire.  
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Material and methods 
Mice 
OF1 mice were purchased from Janvier Labs. (France) and hosted in pathogen free conditions. Male and female 
were equally included in the study.  
Ethical approval 
All applicable international, national, and institutional guidelines for the care and use of animals were followed. 
All procedures performed were in accordance with the ethical standards of the institution at which the studies 
were conducted. 
Gliovascular unit purification  
Gliovascular units (GVU) were isolated from whole brains of OF1 mice as previously described (Yousif et al. 
2007; Boulay et al. 2017). Selective filtration was performed with a negative filtration using a 100 µm nylon 
mesh filter to remove meninges, choroid plexus and periventricular layers, followed by a positive filtering on a 
20 µm nylon mesh filter to retain parenchymal vessels and remove debris from other brain cell types. 
Western-blot 
Proteins were extracted from purified GVUs (5 brains pooled per sample) or brains (1 hemisphere per sample) in 
respectively 50 µL and 500 µL of 2 % SDS per sample with EDTA-free Complete Protease Inhibitor (Roche, 
Mannheim, Germany), sonicated three times at 20 Hz (Vibra cell VCX130, Sonic & Materials, Newtown, USA) 
and centrifuged 20 min at 10 000 g at 4 °C. Supernatants were heated in Laemmli loading buffer for 5 min at 56 
°C. Three independent samples were prepared for each developmental stage (n=3).Protein content was measured 
using the Pierce 660 nm protein assay reagent (Thermo Scientific, Rockford, IL, USA). 20 µg of proteins were 
separated by denaturing electrophoresis in 4-12% NuPAGE gradient gel (or 3-8% Tris Acetate for the P-gP) 
(Thermo Fisher, Waltham, MA, USA) and electrotransferred to nitrocellulose membranes. Membranes were 
analyzed as previously described (Boulay et al. 2017). HRP activity was visualized by ECL using Western 
Lightning plus enhanced chemoluminescence system (Perkin Elmer, Waltham, MA, USA) on a LAS4000 
(Fujifilm, Tokyo, Japan). β-Actin content was used as a loading reference. Semi-quantitative densitometric 
analysis was performed with ImageJ software after scanning the bands.  
P5 to P15 and P15 and P60 samples were loaded and analyzed separately. Global change in expression was 
tested using the non parametric test Kruskal-Wallis (indicated as p-valueKW), and between each stage using the 
Mann-Whitney (indicated as p-valueP5/P10 to p-valueP15/P60). Data are represented as mean ± sd. 
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qPCR  
mRNAs from mice hemispheres were purified using the RNeasy Lipid tissue kit (Qiagen).  cDNA were 
synthesized from 1 μg RNA using Reverse Transcriptase Superscript III kit with random primers and stored at -
20°C. PCR was performed following the droplet PCR procedure (Bio-Rad; Hercules, CA, USA) in 20-μL 
reactions using ddPCR Supermix for Evagreen (Bio-Rad; Hercules, CA, USA) on 1 μL of cDNA diluted in 
water 1/6 for Mlc1 and Glialcam (Hepacam) and 1/60 for Gapdh. Droplets were generated following 
manufacturer’s instructions. PCR cycling was 95 °C for 5 min, and 40 cycles of 95 °C for 30 s and 60 °C for 
1 min. Primers: Hepacam forward 5′-GACCGCCTAAAATCAGAAGCA -3’; Hepacam reverse 5′-
TGGCTCTGTAGCAGGGTTTT-3’; Mlc1 forward 5′-TCAGTGCGATTCCCAACTTTCA-3’; Mlc1 reverse 5′-
GGACCGGGCCGAAATGAT-3’; Gapdh forward 5′-AGGTCGGTGTGAACGGATTTG-3’and Gapdh reverse 
5′- TGTAGACCATGTAGTTGAGGTCA-3’. Positive droplets were counted on a QX200 ddPCR droplet reader 
(Bio-Rad; Hercules, CA, USA) and the QuantaSoft Analysis software (Bio-Rad; Hercules, CA, USA). Mlc1 and 
Hepacam expression were normalized on Gapdh. Change in expression was tested using the Kruskal-Wallis and 
Mann-Whitney non-parametric tests. Data are represented as mean ± sd. 
Immunostaining 
Hippocampal slices: mice were anesthetized with Pentobarbital (600 mg/kg, i.p.) and killed by transcardiac 
perfusion with PBS/PFA 4%. Brain was removed and cut in 30 µm-thick sections using a Leitz (1400) sliding 
microtome. Three animals were analyzed per developmental stage. 
Gliovascular units: GVUs were plated on a glass slide coated with Cell Tak (Corning, Corning, NY, USA) and 
fixed in PBS/PFA 4% for 15 min at room temperature. Three animals were pooled for each developmental stage. 
Hippocampal slices or GVUs were immersed in the blocking solution (PBS/NGS 5%/Triton X-100 0.5%) for 1 h 
at room temperature and incubated with primary antibodies and Isolectin GS-B4 (IB4) diluted in the blocking 
solution 12 h at 4°C. After 3 PBS washes, slices or GVUs were incubated 2 h at room temperature with 
secondary antibodies, rinsed in PBS and finally embedded in Fluormount G. They were analyzed using a 63X 
objective on a Nikon Eclipse Ti microscope (Nikon Instruments, Melville, NY, USA). Proportions of vessels 
with MLC1 or GlialCAM were analyzed with the Chi-squared test with Yates' continuity correction. Among 
GlialCAM-positive vessel segments, the proportion also co-stained for MLC1 were analyzed using an ANOVA/ 
Bartlett’s test and a  Student’s test. Among MLC1-positive vessel segments, the proportion co-stained for 
GlialCAM was analyzed similarly. Data are represented as mean ± sd. 
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Antibodies 
Primary: polyclonal rabbit anti-Aqp4 (1:500) (Sigma, St Louis, MO, USA); polyclonal rabbit anti-Claudin- 5 
(1:250) (Thermo Fisher, Waltham, MA, USA); monoclonal mouse anti-P-gP (1:200) (Enzo Life Sciences, 
Lausen, Switzerland); monoclonal mouse anti-Connexin 43 (1:500) (BD-Biosciences, Franklin Lakes, NJ, U.S.); 
horseradish peroxidase (HRP)-coupled β-actin (1:25000) (Abcam, Cambridge, UK); polyclonal rabbit anti-
GlialCAM (1:200) and monoclonal mouse anti-MLC1 (1:500) (López-Hernández et al. 2011a); Alexa-
conjugated Isolectin GS-B4 (IB4) was used to label the blood vessel walls (1:100) (Thermo Fisher, Waltham, 
MA, USA). 
Secondary: Alexa-conjugated goat anti-mouse and anti-rabbit IgG (1:1000) (Molecular Probes, Eugene, OR, 
USA), HRP-conjugated goat anti-mouse or anti-rabbit IgG (1:2000) (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA).  
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Results  
 
In the adult brain, MLC1 and GlialCAM are not only enriched in astrocyte perivascular endfeet but also 
expressed in perisynaptic astrocyte processes (Sakers et al. 2017) and in oligodendrocytes for GlialCAM 
(Jeworutzki et al. 2012). In addition, during brain development, MLC1 is present in progenitors from the 
ventricular zone (Schmitt et al. 2003). In order to specifically focus our study on astrocyte perivascular proteins, 
we used our recently developed purification technique of the gliovascular unit (GVU), i.e. perivascular endfeet 
attached to brain vessels (Boulay et al. 2015c, 2017) (Fig. 1A). As purification of the GVU has been previously 
obtained only from adult tissues, we first tested if this technique could be developed on early postnatal brains. 
We concentrated our study on parenchymal vessels, depleting our samples from pial vessels by differential 
filtering of the purified vessels (see material and methods) (Yousif et al. 2007). To test the presence of astrocyte 
perivascular endfeet on purified vessels, we performed Aqp4 immunostaining. Blood vessels were labelled by 
Isolectin GS-B4 (IB4). Immunostaining on postnatal day (P) 5 GVUs revealed a continuous Aqp4 labelling at 
the surface of most vessels, as observed in adult (P60) GVUs (Fig. 1B). The proportion of Aqp4-positive GVUs 
was comparable at all stages (Fig. 1C) (P5:83%; P10:88%; P15:96%; P60:93%; p-value=0.45). Performing 
Western-blot quantification on purified GVU protein extracts, we observed a small, although not significant, 
increase of Aqp4 between P5 and P10 followed by a stabilization from P10 onwards (P5:1.0±0.2; P10:1.7±0.9; 
P15:1.8±0.1; P60:1.4±0.1; p-valueKW=0.09) (Fig. 1D and E). The same result was obtained using total brain 
extracts, consistent with the fact that, in the brain, Aqp4 is mostly present in perivascular astrocyte endfeet 
(P5:1.0±0.1; P10:1.5±0.2; P15:1.4±0.1; P60:1.6±0.2; p-valueKW=0.06) (Fig. 1D and E).  To further  validate our 
approach, we tested by Western-blot the copurification of the gap junction channel protein Connexin 43 (Cx43) 
another protein enriched in astrocyte mature endfeet (Ezan et al. 2012). Cx43 was detected in GVU at all stages 
(Fig. S1). Collectively, these results indicated that intact GVUs can be purified from the brain as early as P5 and 
that our purification protocol is a valuable tool to explore the molecular composition of astrocyte perivascular 
endfeet membranes during the postnatal development. 
We next addressed perivascular endfeet expression of MLC1 and GlialCAM during the postnatal development 
from P5. Western-blot of purified GVU protein extracts showed that GlialCAM expression was already 
detectable at P5 (Fig. 2A). Its quantity significantly increased between P10 and P15 and remained stable 
onwards (Fig. 2A and B) (P5:1.0±0.2; P10:1.0±0.03; P15:2.1±0.2; P60:2.6±0.4; p-valueKW=0.002; p-
valueP5/P10=0.4; p-valueP10/P15=0.05; p-valueP15/P60=0.25). In contrast to GVUs, GlialCAM detected in total brain 
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extracts was stable between P10 and P15 (WB, P5:1.0±0.1; P10:1.9±0.2; P15:1.9±0.1; P60:2.2±0.1; p-
valueKW=0.02; p-valueP5/P10=0.05; p-valueP10/P15=0.5; p-valueP15/P60=0.2).  The same was observed at the mRNA 
level. We noticed however an increase from P15 to P60 (qPCR, P5:1.0±0.2; P10:1.2±0.2; P15:0.9±0.2; 
P60:1.8±0.6; p-valueKW=0.003; p-valueP5/P10=0.2; p-valueP10/P15=0.06; p-valueP15/P60=0.03) (Fig. 2B). These 
results suggested a distinct temporal regulation of GlialCAM expression between the GVU and the rest of the 
brain between P10 and P15. We previously found that Aqp4-containing astrocyte endfeet were similarly purified 
at P10 and P15 (Fig. 1). The increase of GlialCAM level in the GVU between P10 and P15 could thus reflect an 
increased expression in endfeet or an increased number of GlialCAM-expressing endfeet. To solve this question, 
we evaluated the proportion of vessels surrounded by GlialCAM-immunolabeled astrocyte endfeet on P10 and 
P15 hippocampal slices. Blood vessels were labeled by IB4 (Fig. 2C and D). The proportion of IB4-positive 
vessels showing a perivascular GlialCAM labeling was similar at P10, P15 and P60 (P5:77%; P10:85%; 
P15:92%; p-valueP10/P15=0.4; p-valueP15/P60=0.9). Since this observation was performed on a restricted part of the 
brain while GVU protein extracts used for Western-blot were obtained from whole brains, we further excluded 
the possibility of regional variation by quantifying the proportion of GlialCAM-positive purified GVU. The 
same proportion was found than on brain sections (Fig. 2E and F) (P5:86%; P10:90%; P15:83%; p-
valueP5/P10=0.8; p-valueP10/P15=0.2). Thus, GlialCAM is expressed around most brain vessels at P10 and its 
expression increases in the GVU between P10 and P15. In addition, while at P10, GlialCAM immunostaining 
was mainly dispersed, it formed clear meshworks surrounding the vessels from P15, suggesting a maturation of 
its subcellular localization (Fig. 2E). 
In contrast to GlialCAM, Western-blot analysis of MLC1 expression in purified GVUs showed a very weak 
signal at P5 and P10, which significantly increased at P15 and was stable onwards (Fig. 3A and B) (P5:1.0±0.1; 
P10:1.6±0.2; P15:9.4±1.4; P60:9.5±1.6; p-valueKW=0.002; p-valueP5/P10=0.4; p-valueP10/P15=0.02; p-
valueP15/P60=0.9). This increase was not detected in total brain extracts both by Western Blot and qPCR 
suggesting that it is an astrocyte endfeet-specific event (WB, P5:1.0±0.06; P10:1.3±0.2; P15:1.6±0.1; 
P60:2.1±0.4; p-valueKW=0.03; p-valueP5/P10=0.7; p-valueP10/P15=0.4; p-valueP15/P60=0.3) (qPCR, P5:1.0±0.4; 
P10:0.9±0.1; P15:0.6±0.2; P60:0.9±0.1; p-valueKW=0.15; p-valueP5/P10=0.9; p-valueP10/P15=0.06; p-
valueP15/P60=0.06) (Fig. 3B). On hippocampal slices, perivascular MLC1 immunostaining was barely detectable 
at P10, while highly present in the astrocyte perivascular endfeet at P15 and P60 (P10:20%; P15:90%; 
P60:100%; p-valueP10/P15=10
-6
; p-valueP15/P60=0.5) (Fig. 3C and D). We further investigated the developmental 
expression of MLC1 on purified GVUs. Astrocyte endfeet perivascular membranes were co-immunostained for 
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Aqp4 and showed a continuous staining as previously observed (Fig. 1B). Interestingly, compared to brain slices, 
more MLC1-immunostained GVUs were observed at P10, and their number still increased between P10, P15 and 
P60 (P10:62%; P15:80%; P60:96%; p-valueP10/P15=0.03; p-valueP15/P60=0.01) (Fig. 3E and F). This difference 
between GVUs and slices was probably due to the fact that, even more strikingly than for GlialCAM, the shape 
of MLC1 staining evolved from isolated puncta on sections at P10 to clear meshworks at P15 (Fig. 3C and E). 
Overall, MLC1 is expressed in astrocyte perivascular endfeet after GlialCAM. It is only weakly detected before 
P10 and significantly increases between P10 and P15. 
In the adult mouse brain, MLC1 and GlialCAM form a protein complex at the perivascular membrane (Hoegg-
Beiler et al. 2014). We addressed the development of this complex in the GVU , analyzing the colocalization of 
both proteins at the gliovascular interface on hippocampal slices (Fig. 4). Since at P10 GlialCAM was more 
widely expressed than MLC1, we first quantified the proportion of perivascular GlialCAMpositive for MLC1 
(Fig. 4). Co-localization of both proteins significantly increased after P10 (ANOVA and Bartlett’s test, p-
value=0.003) and between all stages (p-valueP10/P15=0.03; p-valueP15/P60=0.002). While 67% of GlialCAM 
staining at P10 was also positive for MLC1, it represented 81% at P15 and 97% at P60 (Fig. 4B). These results 
suggested the existence of two pools of GlialCAM in the developing GVUs, associated or not with MLC1, the 
later progressively disappearing after P10. GlialCAM was almost entirely co-localized with MLC1 at P60 as 
shown on GVUs (Fig. 4C). In contrast, MLC1 was systematically colocalized with GlialCAM at all stages. 
Altogether, our results indicate that the P10-P15 time window corresponds to a maturation step of the 
MLC1/GlialCAM complex in astrocyte perivascular endfeet. 
We finally asked if this P10-P15 developmental window might correspond to the parallel maturation of specific 
brain vascular functions. The BBB is an impermeable vascular barrier, which regulates the passage of molecules 
between the blood and the brain. It is induced in the immature endothelium around E15 but still matures during 
late embryonic and postnatal development. BBB integrity depends on the expression of endothelial tight junction 
molecules restricting endothelial paracellular permeability and transporters (Armulik et al. 2010; Daneman et al. 
2010; Tam et al. 2012; Qosa et al. 2015). Here, we characterized the expression of the tight junction protein 
Claudin-5 (Nitta et al. 2003), and the endothelial luminal ATP-Binding Cassette (ABC) transporter P-
glycoprotein (P-gP) which effluxes xenobiotics to the blood (Schinkel et al. 1994, 1996). Strikingly, as observed 
for MLC1 and GlialCAM, Claudin-5 and P-gP levels detected on Western-blots of proteins extracted from 
purified GVUs significantly increased between P10 and P15 (Claudin-5; P5:1.0±0.2; P10:0.8±0.2; P15:2.8±0.3; 
P60:3.3±0.7; p-valueKW=0.0004; p-valueP5/P10=0.7; p-valueP10/P15=0.01; p-valueP15/P60=0.9) (P-gP; P5:1.0±0.1; 
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P10:1.3±0.05; P15:6.0±0.5; P60:10.2±0.7; p-valueKW>0.0001; p-valueP5/P10=0.1; p-valueP10/P15=0.02; p-
valueP15/P60=0.02) (Fig. 5A and B). P-gP level continued to increase after P15. This  increased expression was 
however not associated with a change in  protein distribution within the GVU as both proteins were restricted to 
endothelial cells and present in all vessels (Fig. 5C). Claudin-5 signal lined endothelial cells showing the 
location of tight junctions. P-gP was uniformly detected in the endothelium. These results suggested a parallel 
maturation of the BBB and the astrocyte perivascular endfeet MLC1/GlialCAM complex between P10 and P15. 
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Discussion 
Our results provide the first description of the developmentally regulated perivascular expression of the 
MLC1/GlialCAM complex (summarized in Fig. 5C). We show that GlialCAM precedes MLC1 in the GVU and 
that both proteins increase within the GVU between P10 and P15, thus suggesting a progressive maturation of 
the MLC1/GlialCAM complex after P10. This developmental process is posterior to the formation of Aqp4 
water channels in astrocyte perivascular endfeet, and parallels the maturation of the BBB characterized here by 
the increased expression of some key endothelial BBB components, Claudin-5 and P-gP. 
We previously reported that isolating the GVU allows the characterization of the molecular properties of 
astrocyte endfeet and the other cellular components of the GVU, endothelial cells, pericytes and smooth muscles 
cells (Boulay et al. 2015a, b, c; Mazaré et al. 2018). Here, we provide the first evidence that this strategy can also 
be applied to characterize the GVU during brain development. In particular we determined the evolution of 
perivascular pool of astrocyte proteins within the GVU, which were either stable from P5 for Aqp4, or increasing 
between P10 and P15 for the MLC1/GlialCAM complex. Finally, the GVU purification allows to distinguish and 
compare the perivascular and parenchymal counterparts of astrocyte proteins as evidenced here for MLC1 which 
was highly enriched between P10 and P15 in the GVU fraction while constant in the brain (Fig. 3). Altogether, 
GVU purification is therefore a valuable tool to study astrocyte perivascular molecular properties during 
development. 
Knowledge of astrocyte perivascular endfeet development is elusive. This question has been almost exclusively 
studied through the prism of Aqp4 (Lunde et al. 2015). Here, we found that most P5-vessels were covered with 
Aqp4-containing endfeet (Fig. 1), which confirms previous results based on brain slices showing that coverage 
of the brain vascular compartment by astrocyte endfeet is complete at P5 (Ezan et al. 2012). Alike Aqp4, 
GlialCAM, but not MLC1, appears to be another constituent of these early endfeet. Between P10 and P15, a 
strong increase in GlialCAM and MLC1 occurs, associated with the formation of the MLC1/GlialCAM complex 
detected by the colocalization of both proteins. Intriguingly, Mlc1 and Glialcam mRNA levels were stable from 
P5 to P15 suggesting thus that the increase of MLC1 and GlialCAM in the GVU is probably regulated by 
mechanisms involving post-transcriptional regulations. To further address the importance of this postnatal period 
in the GVU development, we examined the expression of Cx43, another astrocyte endfeet-enriched protein 
(Ezan et al. 2012) (Fig. S1). Corroborating previous observations obtained on cortical slices (Ezan et al. 2012), 
we found an increase between P10 and P15 both in GVUs (P5:1.0±0.2; P10:1.5±0.4; P15:3.9±0.2; P60:3.4±0.6; 
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p-valueKW=0.001; p-valueP5/P10=0.7; p-valueP10/P15=0.02; p-valueP15/P60=0.4) and in brain extracts (P5:1.0±0.07; 
P10:1.3±0.2; P15:2.0±0.2; P60:1.8±0.2; p-valueKW=0.006; p-valueP5/P10=0.2; p-valueP10/P15=0.05; p-
valueP15/P60=0.7). Altogether, these results indicated that despite the extensive Aqp4 perivascular expression at 
P5, astrocyte perivascular endfeet are not mature at this stage and that the P10 to P15 postnatal period could 
represent an important step of astrocyte endfeet maturation with the expression of Cx43 and the formation of the 
MLC1/GlialCAM complex at the junctions of astrocyte endfeet. A recent report identified a two-step maturation 
of astrocyte perisynaptic processes, with the formation of major branches at P7 and of finer processes 
ensheathing synapses at P21 (Stogsdill et al. 2017). A similar mechanism could apply to perivascular processes 
during postnatal development.  
Our colocalization study suggested that two pools of GlialCAM might exist during the astrocyte perivascular 
endfeet development, with or without MLC1 (Fig.4). Since GlialCAM has been implicated in cell-matrix 
adhesion and cell motility processes (Chung Moh et al. 2005; Favre-Kontula et al. 2008), it might participate to 
the formation of astrocyte perivascular processes at P5. In contrast, from P10, GlialCAM increasingly 
colocalized with MLC1. In vitro and in vivo observations have shown that GlialCAM is essential for the 
localization of MLC1 in astrocyte membranes (López-Hernández et al. 2011b; Hoegg-Beiler et al. 2014). 
Similarly, Cx43 has been shown to interact with GlialCAM and to depend on GlialCAM to be correctly targeted 
to the membrane (Wu et al. 2016). Thus, between P10 and P15, GlialCAM might be necessary to drive the 
polarized localization of several astrocyte perivascular endfeet proteins. 
Astrocytes are known to maintain the brain vascular properties such as BBB functions (Alvarez et al. 2013; 
Obermeier et al. 2013). However, astrocyte contribution during their postnatal maturation has never been 
documented. Our results provide evidence that the maturation of the MLC1/GlialCAM complex coincides with 
an increased expression of Claudin-5 and P-gP which are key endothelial proteins for BBB integrity. Thus, 
postnatal astrocyte endfeet and BBB maturation might be coordinated events. Interestingly, MLC patients as 
well as MLC mouse models with overexpression of MLC1 (Sugio et al. 2017), or deletion of MLC1 (Dubey et 
al. 2015) or GlialCAM (Bugiani et al. 2017) display cerebral oedema and macrocephaly during the first year of 
life in patients and around 3 weeks postnatal in mouse models. These data suggest that an abnormal development 
of the MLC1/GlialCAM complex may affect the postnatal development of the GVU resulting in impaired BBB 
maturation and oedema formation contributing to the MLC pathological process. MLC1/GlialCAM complex has 
also been shown to play a role in maintaining brain ion–water homeostasis (Ridder et al. 2011; Capdevila-Nortes 
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et al. 2013b). Thus, MLC brain oedema could also be linked to an abnormal parenchymal water circulation in 
parallel to the Aqp4-mediated glymphatic system recently discussed (Iliff et al. 2012, 2014; Xie et al. 2013).  
Altogether, our results shed new light on the gliovascular unit postnatal development. Through the study of the 
MLC1/GlialCAM complex, we demonstrate the existence of a progressive postnatal astrocyte endfeet molecular 
maturation and polarization, which might participate to the functional maturation of the gliovascular unit.  
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Figure legends 
Figure 1: Purification of gliovascular units from postnatal developing brains 
A. Schematic representation of the gliovascular unit (GVU) purification process indicating its cellular 
components. A, astrocyte; AE, astrocyte endfeet; E, endothelial cell; M, mural cell; L, vessel lumen;. An 
astrocyte is shown in red. B. Confocal projection images of purified GVUs from P5 and P60 brains 
immunolabelled for Aqp4 (red) showing that astrocyte perivascular membranes are co-purified with brain 
vessels as early as P5. Nuclei are labelled with Hoechst (blue) and blood vessel walls with IB4 (grey). C. 
Quantification of the proportion of Aqp4-positive GVU segments between P5 and P60. Most purified GVUs 
contain astrocyte Aqp4-positive perivascular membranes. This proportion does not change after P5. D, E. 
Western-blot analysis (D) and quantification (E) of whole brain- and GVU-purified proteins between P5 and 
P60. β-actin is used as a loading control. The level of Aqp4 in purified GVUs and brain remains constant during 
postnatal development. ns, p>0.05. GVU, gliovascular unit; IB4, Isolectin GS-B4. 
Figure 2: Postnatal expression of GlialCAM in astrocyte perivascular endfeet 
A.Western-blot analysis and quantification of whole brain- and GVU-purified proteins between P5 and P60. β-
actin is used as a loading control. GlialCAM expression significantly increases between P10 and P15 in the 
purified GVUs and between P5 and P10 in the brain. B. qPCR analysis of whole brain mRNAs between P5 and 
P60. Gapdh is used as a loading control. GlialCAM expression significantly increases at P60. .. C-F. Projection 
confocal images and quantification of GlialCAM-immunolabelled vessels (green) in hippocampal slices (C, D) 
and purified GVUs (E, F) at P10 and P15. Nuclei are labelled with Hoechst (grey) and blood vessel wall with 
IB4 (red). GlialCAM is present around a majority of brain vessels. *, p<0.05; ns, p>0.05. WB, Western Blot; 
GVU, gliovascular unit; IB4, Isolectin GS-B4. 
Figure 3: Postnatal expression of MLC1 in astrocyte perivascular endfeet 
A.Western-blot analysis and quantification of whole brain- and GVU-purified proteins between P5 and P60. β-
actin is used as a loading control. MLC1 expression significantly increases between P10 and P15 in the purified 
GVUs but not in the brain. B. qPCR analysis of whole brain mRNAs between P5 and P60. Gapdh is used as a 
loading control. MLC1 expression is constant. C-F. Projection images and quantification of MLC1-
immunolabelled vessels (green) in hippocampal slices (C, D) and purified GVU (E, F) at P10 and P15. Nuclei 
are labelled with Hoechst (grey), blood vessel wall with IB4 (red) and astrocyte endfeet are immunolabelled for 
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Aqp4 (red). MLC1-positive vessel proportion increases mainly between P10 and P15. ***, p<0.001; *, p<0.05; 
ns, p>0.05. WB, Western Blot; GVU, gliovascular unit; IB4, Isolectin GS-B4. 
Figure 4: Postnatal maturation of the astrocyte endfeet MLC1/GlialCAM complex  
A. Representative projection image of P10 brain slices immunolabelled for MLC1 (green) and GlialCAM (red) 
showing GlialCAM colocalized with MLC1 (arrow) or not (arrowhead). Blood vessel wall are labelled with IB4 
(grey). B. Quantification of perivascular GlialCAM colocalized with MLC1 (black) and perivascular MLC1 
colocalized with GlialCAM (white). Colocalization of GlialCAM with MLC1 increases significantly after P10 
while MLC1 is always colocalized with GlialCAM. C. Projection image of a P60-purified GVU immunolabelled 
for MLC1 (green) and GlialCAM (red) showing extensive colocalization into networks delimiting astrocyte 
endfeet. Nuclei are labelled with Hoechst (blue) and blood vessel wall with IB4 (grey).**, p<0.01 *, p<0.05; ns, 
p>0.05. GVU, gliovascular unit; IB4, Isolectin GS-B4. 
Figure 5: P10-P15, a temporal window for the GVU maturation. 
A, B. Western-blot analysis (A) and quantification (B) of the tight junction protein Claudin-5 and the ABC 
transporter P-Glycoprotein (P-gP), on protein extracts from purified GVUs between P5 and P60. β-actin is used 
as a loading control. Both proteins increase significantly between P10 and P15 and P60 for P-gP. C. 
Representative projection image of P10, P15 and P60-purified GVU immunolabelled for P-gP (green) and 
Claudin-5 (red). Nuclei are labelled with Hoechst (blue) and blood vessel wall with IB4 (grey).  D. Visual 
abstract of the results outlining the changes observed between P10, P15 and P60 within the GVU. At P10, Aqp4 
(dark blue) is present in all endfeet, GlialCAM (red) in almost all endfeet, while MLC1 (green) is restricted to 
some endfeet. Both MLC1 and GlialCAM increase significantly within GVU between P10 and P15. This 
increase is associated with a progressive colocalization of both proteins (yellow), indicating a maturation of the 
MLC1/GlialCAM complex at the junctions between endfeet. This maturation of MLC1/GlialCAM correlates 
with an increased expression of endothelial proteins Claudin-5 (light blue) and P-gP (black) which participate to 
the BBB formation. *, p<0.05; ns, p>0.05. GVU, gliovascular unit. 
Figure S1: Postnatal expression of Connexin 43 in astrocyte perivascular endfeet  
Western-blot analysis (A) and quantification (B) of Connexin 43 (Cx43) expression in purified GVU and whole 
brains and between P5 and P60. β-actin is used as a loading control. The variable presence of the two upper 
Cx43 phosphorylated bands in the P60 samples is linked to the migration protocol. Cx43 increases between P10 
and P15 both in GVUs and brain. *, p<0.05; ns, p>0.05. GVU, gliovascular unit.  
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Figure S2: Detailed Western Blot results 
Detailed Western-Blot analysis presented in the figures. Squared areas indicate the bands analyzed for 
quantification. Saturated signal present on the MLC1 (GVU) Western-Blot is due to rehybridation of the 
membrane with β-actin. GVU, gliovascular unit. 
 
